Begent RH - Search Results

1

Antibody-directed enzyme prodrug therapy: pharmacokinetics and plasma levels of prodrug and drug in a phase I clinical trial.

Martin J, Stribbling SM, Poon GK, Begent RH, Napier M, Sharma SK, Springer CJ. Martin J, et al. Among authors: begent rh. Cancer Chemother Pharmacol. 1997;40(3):189-201. doi: 10.1007/s002800050646. Cancer Chemother Pharmacol. 1997. PMID: 9219501 Clinical Trial.

2

Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent.

Pedley RB, Sharma SK, Boxer GM, Boden R, Stribbling SM, Davies L, Springer CJ, Begent RH. Pedley RB, et al. Among authors: begent rh. Cancer Res. 1999 Aug 15;59(16):3998-4003. Cancer Res. 1999. PMID: 10463598

3

Antibody-directed enzyme prodrug therapy: efficacy and mechanism of action in colorectal carcinoma.

Napier MP, Sharma SK, Springer CJ, Bagshawe KD, Green AJ, Martin J, Stribbling SM, Cushen N, O'Malley D, Begent RH. Napier MP, et al. Among authors: begent rh. Clin Cancer Res. 2000 Mar;6(3):765-72. Clin Cancer Res. 2000. PMID: 10741695 Clinical Trial.

4

Measurement of the critical DNA lesions produced by antibody-directed enzyme prodrug therapy (ADEPT) in vitro, in vivo and in clinical material.

Webley SD, Francis RJ, Pedley RB, Sharma SK, Begent RH, Hartley JA, Hochhauser D. Webley SD, et al. Among authors: begent rh. Br J Cancer. 2001 Jun 15;84(12):1671-6. doi: 10.1054/bjoc.2001.1843. Br J Cancer. 2001. PMID: 11401322 Free PMC article.

5

Effect of cyclosporine on immunogenicity of a bacterial enzyme carboxypeptidase G2 in ADEPT.

Sharma SK, Bagshawe KD, Melton RG, Begent RH. Sharma SK, et al. Among authors: begent rh. Transplant Proc. 1996 Dec;28(6):3154-5. Transplant Proc. 1996. PMID: 8962222 No abstract available.

6

Recombinant anti-carcinoembryonic antigen antibodies for targeting cancer.

Chester KA, Mayer A, Bhatia J, Robson L, Spencer DI, Cooke SP, Flynn AA, Sharma SK, Boxer G, Pedley RB, Begent RH. Chester KA, et al. Among authors: begent rh. Cancer Chemother Pharmacol. 2000;46 Suppl:S8-12. doi: 10.1007/pl00014055. Cancer Chemother Pharmacol. 2000. PMID: 10950140 Review.

7

The importance of measuring quality of life in phase I/II trials of cancer therapy--the effects of antibody targeted therapy: Part I.

Hope-Stone LD, Napier MP, Begent RH, Cushen N, O'Malley D. Hope-Stone LD, et al. Among authors: begent rh. Eur J Cancer Care (Engl). 1997 Dec;6(4):267-72. doi: 10.1046/j.1365-2354.1997.00053.x. Eur J Cancer Care (Engl). 1997. PMID: 9460345 Clinical Trial.

8

Catalytic activity of an in vivo tumor targeted anti-CEA scFv::carboxypeptidase G2 fusion protein.

Bhatia J, Sharma SK, Chester KA, Pedley RB, Boden RW, Read DA, Boxer GM, Michael NP, Begent RH. Bhatia J, et al. Among authors: begent rh. Int J Cancer. 2000 Feb 15;85(4):571-7. Int J Cancer. 2000. PMID: 10699932 Free article.

9

Clinical applications of phage-derived sFvs and sFv fusion proteins.

Chester KA, Bhatia J, Boxer G, Cooke SP, Flynn AA, Huhalov A, Mayer A, Pedley RB, Robson L, Sharma SK, Spencer DI, Begent RH. Chester KA, et al. Among authors: begent rh. Dis Markers. 2000;16(1-2):53-62. doi: 10.1155/2000/672706. Dis Markers. 2000. PMID: 11360829 Free PMC article. Review.

10

Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library.

Begent RH, Verhaar MJ, Chester KA, Casey JL, Green AJ, Napier MP, Hope-Stone LD, Cushen N, Keep PA, Johnson CJ, Hawkins RE, Hilson AJ, Robson L. Begent RH, et al. Nat Med. 1996 Sep;2(9):979-84. doi: 10.1038/nm0996-979. Nat Med. 1996. PMID: 8782454 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

215 results

Search Page